Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples

被引：0
|
作者：
Sewastjanow, Matheus
Yamashita, Kohei
Iwata, Kenneth K.
Moran, Diarmuid
Elsouda, Dina
Pizzi, Melissa
Vicentini, Ernesto Rosa
Shanbhag, Namita
Ta, Anh
Waters, Rebecca
Chatterjee, Deyali
Ajani, Jaffer
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2141
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/ gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase study
    Liu, J. J.
    Yu, X.
    Zhang, J.
    Yang, J.
    Yue, J.
    Sun, Y.
    Pan, Y.
    Sun, M.
    Qin, Y.
    Shen, L.
    Song, R.
    Ruan, J.
    Zhou, A.
    Mou, Y.
    Liu, Z.
    Liu, Z.
    Morris, M.
    Aghmesheh, M.
    Tazbirkova, A.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S160 - S160
  • [22] Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study
    Guilan Hu
    Wenjia Zhu
    Yu Liu
    Yuan Wang
    Zheng Zhang
    Shikun Zhu
    Wenwen Duan
    Peipei Zhou
    Chao Fu
    Fang Li
    Li Huo
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 2634 - 2644
  • [23] Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
    Bang, Y-J.
    Shen, L.
    Kang, Y-K.
    Chao, Y.
    Soo, H. H. F.
    Sunpaweravong, P.
    Moran, D.
    Guerrero, A.
    Li, R.
    Pavese, J.
    Matsangou, M.
    Bhattacharya, P.
    Shitara, K.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1527 - S1528
  • [24] Development of Claudin 18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-claudin 18.2 monoclonal antibody osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinoma
    Alderson, Hayley
    Lefley, Katie
    Fregoso, Lesly
    Bharadwaj, Achintya
    Castellanos-McKenney, Dan
    Tabuena-Frolli, Siena
    Kell, Donna
    Yao, Xinlai
    Qian, Xueming
    Xu, Li
    Germa, Caroline
    Oroudjev, Emin
    CANCER RESEARCH, 2024, 84 (06)
  • [25] A retrospective, pathologist-based assessment of immunohistochemistry assay for CLDN18.2 expression in digestive system adenocarcinoma
    Xu, M.
    Tan, C.
    Wang, X.
    Wang, X.
    Weng, W.
    Zhang, M.
    Wang, L.
    Sun, H.
    Ni, S.
    Sheng, W.
    Huang, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S93 - S93
  • [26] Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
    Shah, Manish A.
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Lordick, Florian
    Van Cutsem, Eric
    Plazas, Javier Gallego
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Soo Hoo, Hwoei Fen
    Turk, Haci Mehmet
    Oh, Mok
    Park, Jung Wook
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Xu, Rui-Hua
    NATURE MEDICINE, 2023, 29 (08) : 2133 - +
  • [27] Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
    Manish A. Shah
    Kohei Shitara
    Jaffer A. Ajani
    Yung-Jue Bang
    Peter Enzinger
    David Ilson
    Florian Lordick
    Eric Van Cutsem
    Javier Gallego Plazas
    Jing Huang
    Lin Shen
    Sang Cheul Oh
    Patrapim Sunpaweravong
    Hwoei Fen Soo Hoo
    Haci Mehmet Turk
    Mok Oh
    Jung Wook Park
    Diarmuid Moran
    Pranob Bhattacharya
    Ahsan Arozullah
    Rui-Hua Xu
    Nature Medicine, 2023, 29 : 2133 - 2141
  • [28] Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
    Shitara, Kohei
    Xu, Rui-Hua
    Moran, Diarmuid Martin
    Guerrero, Abraham
    Li, Ran
    Pavese, Janet
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Ajani, Jaffer A.
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial
    Botta, Gregory P.
    Kelly, Ronan Joseph
    Jin, Zhaohui
    Ma, Hong
    Ku, Geoffrey Yuyat
    Zhao, Dan
    Mehta, Rutika
    Carnevale, Julia C.
    Sierra, Gloria
    Jia, Jie
    Baffa, Raffaele
    Li, Zhonghai
    Kim, Dae Won
    Yoon, Harry H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 356 - 356
  • [30] Claudin 18.2 determination in locally advanced gastric and gastroesophageal adenocarcinoma treated with neoadjuvant chemotherapy.
    Gervaso, Lorenzo
    Cella, Chiara Alessandra
    Lobrano, Renato
    De Pascale, Stefano
    Benini, Lavinia
    Spada, Francesca
    De Roberto, Giuseppe
    Romario, Uberto Fumagalli
    Rocco, Elena Guerini
    Fazio, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 492 - 492
12345